nav-left cat-right

Evotec Announces Research Agreement With Biogen Idec

HAMBURG, Germany and OXFORD, UK, Sept. 9, 2009 (GLOBE NEWSWIRE) -- Evotec AG
(Frankfurt:EVT) (Nasdaq:EVTC), a leading provider in the discovery and
development of novel small molecule drugs, today announced that it has entered
into a research agreement with Biogen Idec (Nasdaq:BIIB), a leading
biopharmaceutical company headquartered in Cambridge, Mass., USA.

Evotec will use its expertise and technologies in protein production, assay
development and high throughput screening to identify hit molecules for Biogen
Idec. Under the research agreement Evotec will screen a target selected by
Biogen Idec with the option to add further targets as agreed. Evotec will
provide Biogen Idec with access to its full range of screening technologies and
diverse library of high quality compounds and will use its expertise in protein
production and assay development to develop new assays for the target.

Dr. Mark Ashton, Evotec's EVP, Business Development commented: "We believe that
the quality of future drug candidates is very much dependent on the
identification of high quality starting points. To this end we have established
a platform of screening technologies that have been proven to identify
high-class hit molecules. We are looking forward to working with Biogen Idec and
identifying interesting hit compounds for them."

Evotec has built a comprehensive platform of hit finding technologies that allow
it to screen challenging targets and identify new classes of hit compounds that
can be progressed towards new treatments for various diseases. These proven
screening technologies coupled with Evotec's high quality screening library have
been shown to unlock numerous biological targets and identify excellent start
points for subsequent optimization.

No financial details are disclosed.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule
drugs. The Company has built substantial drug discovery expertise and an
industrialized platform that can drive new innovative small molecule compounds
into the clinic. In addition, Evotec has built a deep internal knowledge base in
the treatment of diseases related to neuroscience, pain, and inflammation.
Leveraging these skills and expertise the Company intends to develop
best-in-class differentiated therapeutics and deliver superior science-driven
discovery alliances with pharmaceutical and biotechnology companies.

Evotec has long-term discovery alliances with partners including Boehringer
Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. The Company has a P2X7
antagonist for the treatment of inflammatory diseases in clinical development
and a series of preclinical compounds and development partnerships, including a
strategic alliance with Roche for EVT 101, a subtype selective NMDA receptor
antagonist, for use in treatment-resistant depression. For additional
information please go to

Forward-looking statements

Information set forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. Such forward-looking
statements include, but are not limited to, statements about our expectations
and assumptions concerning regulatory, clinical and business strategies, the
progress of our clinical development programs and timing of the results of our
clinical trials, strategic collaborations and management's plans, objectives and
strategies. These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the risks and
uncertainties include, among other things: risks that the Company may be unable
to reduce its cash burn through recent restructuring and cost containment
measures and may not recognize the results of such measures within the expected
timeframe; risks that product candidates may fail in the clinic or may not be
successfully marketed or manufactured; the risk that we will not achieve the
anticipated benefits of our collaborations, partnerships and acquisitions in the
timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical
trials; our inability to further identify, develop and achieve commercial
success for new products and technologies; the risk that competing products may
be more successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual property
and the cost of enforcing or defending our intellectual property rights; our
failure to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials
may not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug candidates; and
risks of new, changing and competitive technologies and regulations in the U.S.
and internationally. The list of risks above is not exhaustive. Our most recent
Annual Report on Form 20-F, filed with the Securities and Exchange Commission,
and other documents filed with, or furnished to the Securities and Exchange
Commission, contain additional factors that could impact our businesses and
financial performance. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any such statements to reflect any
change in our expectations or any change in events, conditions or circumstance
on which any such statement is based.
Source: Reuters